Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787965 · ClinicalTrials.gov registry record
Opicapone Treatment Initiation Open-Label Study
A clinical trial of Parkinson Disease, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- 239
- Enrollment target
- 6
- Study locations
NCT04787965: Completed study of Parkinson Disease, sponsored by Neurocrine Biosciences.
NCT04787965 is a study of Parkinson Disease that has completed, run by Neurocrine Biosciences. The registered enrollment target is 239 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04787965, a study of Parkinson Disease, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- 239 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations
Primary Outcome
Reason for initiating treatment and discontinuation
Conditions Studied
Interventions
- DRUG Opicapone
Study Locations (6)
Virginia
- Neurocrine clinical site - Christiansburg
- Neurocrine clinical site - Norfolk
California
- Neurocrine clinical site - Los Gatos
Tennessee
- Neurocrine clinical site - Memphis
Washington
- Neurocrine clinical site - Auburn
West Virginia
- Neurocrine clinical site - Crab Orchard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-08-04 |
What the finished NCT04787965 record still lists
NCT04787965 is an observational study that tracks outcomes without assigning an intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Opicapone is the first listed.
NCT04787965 lists 6 locations in 5 states (Virginia, California, Tennessee).
Frequently Asked Questions
What is clinical trial NCT04787965 about?
NCT04787965 is a clinical study titled "Opicapone Treatment Initiation Open-Label Study". This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations
What is the current status of trial NCT04787965?
This trial is currently completed. The enrollment target is 239 participants. The study started on 2021-03-01. Estimated completion is 2022-08-04.
What conditions does trial NCT04787965 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04787965?
The interventions under investigation include: Opicapone (DRUG).
Who is sponsoring clinical trial NCT04787965?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04787965 being conducted?
This trial has 6 study locations across California, Tennessee, Virginia, Washington, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04787965's enrollment target sits among peer trials
239 41st of 297 higher than 257 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI